EP Patent

EP2132206B1 — Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung

Assigned to Bayer Intellectual Property GmbH · Expires 2015-04-01 · 11y expired

What this patent protects

Patent listed against Kerendia.

Drugs covered by this patent

Patent Metadata

Patent number
EP2132206B1
Jurisdiction
EP
Classification
—
Expires
2015-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.